Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Daclatasvir/Asunaprevir/Beclabuvir on Oral Contraceptive PK
NCT02103569Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of beclabuvir, daclatasvir and asunaprevir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Primary endpoints: Area under the concentration versus time curve in 1 dosing interval and Maximum observed plasma concentration. Started Apr 2014; status: completed.
02
Drugs
beclabuvirdaclatasvirasunaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02103569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103569.